跳至主要内容
临床试验/NCT00428298
NCT00428298已完成2 期

A Double Blind Placebo Controlled Study of Valacyclovir in Cognitive Impairment and Mood Symptoms of Bipolar Disorder

Johns Hopkins University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2007年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
1
主要终点
Percent Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status at 16 Weeks

研究概览

简要总结

This is a sixteen week, randomized, double-blind add-on study of valacyclovir versus placebo in approximately 60 outpatients meeting diagnostic criteria according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV Bipolar I or II disorder, testing positive for HSV-1 and who have demonstrable cognitive impairment defined as a total score of less than 85 (one standard deviation from the normal range) on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Each patient will be randomized to double-blind treatment with either valacyclovir or placebo for sixteen weeks. All subjects will be maintained on a stable regimen of psychiatric drugs prescribed by their treating psychiatrist. Patients will be evaluated every 2 weeks by the treatment team and mood rating scales will be administered at each visit including the Young Mania Rating Scale (YMRS) and the Montgomery Asberg Depression Rating Scale (MADRS). The RBANS will be administered again at 8 and 16 weeks. Both the treatment team and the patient will remain blinded during the course of the study. Following the active treatment phase, patients will receive treatment as clinically indicated.

Primary Hypothesis:

Valacyclovir will be superior to placebo in reducing cognitive symptoms associated with bipolar disorder in subjects who have been previously infected with Herpes Simplex virus I (HSV-1).

Secondary Hypothesis:

Valacyclovir will be superior to placebo in reducing mood symptoms associated with bipolar disorder in subjects who have been previously infected with HSV-1.

详细描述

Background

Herpes Viral Infections and Mental Illness. Recent studies have suggested that chronic, recurrent infections with the herpes family of viruses may play a role in chronic mental illnesses such as schizophrenia and bipolar disorder. Several studies have indicated that individuals with schizophrenia have evidence of increased exposure to Herpes virusesthough this has not been found in all studies . Leweke et al found that untreated individuals with recent first episode schizophrenia had increased levels of serum and cerebrospinal fluid (CSF) immunogloublin G (IgG) antibodies to Cytomegalovirus (CMV) and Toxoplasma gondii in comparison to controls without psychiatric illness. Notably, serum immunoglobulin M (IgM) levels were not increased indicating that infection had not occurred recently. Treated individuals with schizophrenia had similar antibody levels as controls. Finally, Dickerson et al have recently shown that previous Herpes Simplex Virus -1 (HSV-1) infection is associated with cognitive impairment in bipolar disorder, with a relative risk of 22.2 and that this risk was increased in the presence of the catechol-o-methyltransferase (COMT) 158 Val/Val genotype.

It is well known that active replication of herpes viruses may occur after extended periods of latency. It has also been shown active replication of the virus in the central nervous system may be triggered by environmental or psychosocial stressors and cause mood and even psychotic symptoms. Taken together with the evidence of increased exposure to Herpes viruses found in individuals with schizophrenia and bipolar disorder, one hypotheses that remains to be tested is that episodic reactivation of Herpes Simplex 1 (HSV-1) in the brain triggered by environmental stressors could be a pathogenic mechanism contributing to symptomatology in a subset of bipolar disorder and schizophrenic patients.

Cognitive Impairment in Bipolar Disorder

Cognitive, or neuropsychological, functioning is one of the major domains of symptomatology in major mental illness. While cognitive impairment in schizophrenia has been long established, neuropsychological functioning in bipolar disorder has been less extensively studied. Nevertheless, there is evidence that patients with mood disorders frequently manifest cognitive deficits in attention, executive and memory functions. While symptomatic bipolar disorder patients have been shown to have widespread cognitive abnormalities, evidence from many studies also supports the hypothesis that there are persistent residual cognitive impairments in patients in the euthymic phase of illness. As noted above, Dickerson et al have very recently shown an association between HSV-1 seropositivity and cognitive dysfunction in bipolar disorder (2006).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be between the ages of 18-65
  • Have a diagnosis of Bipolar I or II disorder (as defined by DSM-IV)
  • Be in active treatment with an outpatient psychiatrist
  • Test positive for HSV1
  • Demonstrate cognitive impairment on the RBANS as defined by a total score of less than 85 (i.e. greater than one standard deviation below normal).

排除标准

  • Either pregnant or nursing
  • Have been diagnosed with any serious, unstable illnesses including HIV infection or other immunodeficiency condition, hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and hypertension), endocrinologic, neurologic, immunologic, or hematologic disease. Illnesses that are currently well controlled and being treated are not grounds for exclusion.
  • Have a history of hypersensitivity or intolerance to valacyclovir or acyclovir
  • Meet criteria for DSM-IV substance abuse (except nicotine and caffeine) within the past 90 days
  • Had Electroconvulsive Therapy (ECT) within three months prior to randomization
  • Judged to be at serious suicidal risk; inability to provide informed consent.

研究组 & 干预措施

Active Treatment Valacyclovir

Experimental

Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.

干预措施: Valacyclovir (Drug)

Placebo Treatment

Placebo Comparator

Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.

干预措施: Placebo (Drug)

结局指标

主要结局

Percent Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status at 16 Weeks

时间窗: 16 weeks

The RBANS is a brief, independently administered measurement of cognitive decline or improvement. The test is comprised of 12 subtests which comprise 5 domains. The age of the participant and the scores from each domain inform the total RBANS score (Index Score) analyzed in this study. The range for total score is 40-160. If the total score for a subject increases this denotes improved performance on the RBANS. The RBANS was administered at baseline and 16 weeks.

次要结局

  • Change From Baseline in Montgomery Asberg Depression Score at 16 Weeks(16 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Research Study of Bipolar Mood Symptoms and... | 临床试验